Gene therapy (FT-003) for wet AMD
Part of Eyes & vision clinical trials.
This trial tests a new gene therapy, FT-003, for people with wet AMD. It aims to see if a single treatment can help stop vision loss and may reduce the need for frequent eye injections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing and able to follow the study's schedule and instructions.
- You are between 50 and 80 years old.
- You have been diagnosed with wet age-related macular degeneration (wet AMD).
- You have active abnormal blood vessels in your eye from wet AMD.
- Your vision in the study eye is between 20/32 and 20/800 on a standard eye chart.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
This trial tests a gene therapy designed to treat wet age-related macular degeneration (AMD), a condition that causes rapid vision loss. The therapy aims to stop the growth of abnormal blood vessels in the eye, potentially preserving or improving vision.
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
This trial tests a gene therapy (KH658) as a one-time treatment for wet macular degeneration. It's for people whose condition has been stabilized with anti-VEGF injections, and aims to see if it is safe and can reduce the need for frequent eye injections.
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.